Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04398628 · ClinicalTrials.gov registry record
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
A clinical trial of Thrombosis and Hemophilia, sponsored by American Thrombosis and Hemostasis Network.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 20
- Study locations
NCT04398628 is a study of Thrombosis and Hemophilia that is actively recruiting participants, run by American Thrombosis and Hemostasis Network. The registered enrollment target is 3,000 participants, above the 363-participant average among 28 other Thrombosis trials with a reported enrollment target (726% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT04398628, a study of Thrombosis and Hemophilia, is actively recruiting participants, sponsored by American Thrombosis and Hemostasis Network.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5 In 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7 With this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8
Conditions Studied
Study Locations (20)
California
- Orthopaedic Institute for Children HTC - Los Angeles
- Childrens Hospital Los Angeles - Los Angeles
- UCSF Benioff Children's Hospital Oakland - Oakland
- University of California at Davis Hemophilia Treatment Center - Sacramento
- Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program - San Bernardino
- Hemophilia & Thrombosis Treatment Center at UC San Diego Health - San Diego
- Rady Children's Hospital San Diego - San Diego
- University of California, San Francisco Hemophilia & Thrombosis Center - San Francisco
Florida
- University of Florida Hemophilia Treatment Center - Gainesville
- University of Miami Comprehensive Hemophilia Treatment Center - Miami
- Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders - Orlando
- Johns Hopkins All Children's Hospital - St. Petersburg
- St. Joseph's Hospital Center for Bleeding & Clotting Disorders - Tampa
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale Hemophilia Treatment Center - New Haven
District of Columbia
- Georgetown University - Washington D.C.
- Children's National Hemophilia Center - Washington D.C.
Arizona
- Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Center for Bleeding Disorders - Little Rock
Delaware
- Delaware Hemophilia Treatment Center - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04398628
The ClinicalTrials.gov registry entry for NCT04398628 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 363-participant average among 28 other Thrombosis trials with a reported enrollment target (726% higher). The listed sponsor is American Thrombosis and Hemostasis Network, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Thrombosis appearing as the primary indexed condition, and to 0 interventions.
NCT04398628 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04398628 about?
NCT04398628 is a clinical study titled "ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders". In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond ...
What is the current status of trial NCT04398628?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2020-09-30. Estimated completion is 2035-12.
What conditions does trial NCT04398628 study?
This clinical trial studies the following conditions: Thrombosis, Hemophilia, Von Willebrand Diseases, Bleeding Disorder, Thrombophilia.
Who is sponsoring clinical trial NCT04398628?
This trial is sponsored by American Thrombosis and Hemostasis Network, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04398628 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
-
Vascular Lab Resource (VLR) Biorepository
RECRUITING
-
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
RECRUITING
-
Platelet Volunteers, Longitudinal and Multi-omic Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.